Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.

Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA.

Gynecol Oncol. 2018 Jun;149(3):525-530. doi: 10.1016/j.ygyno.2018.03.043. Epub 2018 Mar 15.

PMID:
29550184
2.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.

Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.

PMID:
29191972
3.

Are patients willing to travel for better ovarian cancer care?

Shalowitz DI, Nivasch E, Burger RA, Schapira MM.

Gynecol Oncol. 2018 Jan;148(1):42-48. doi: 10.1016/j.ygyno.2017.10.018. Epub 2017 Nov 1.

PMID:
29079037
4.

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.

Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ; NRG Oncology/Gynecologic Oncology Group.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx066.

PMID:
29059426
5.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

PMID:
28807367
6.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

PMID:
28756902
7.

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.

Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, Cella D, Havrilesky LJ, Burger RA, Monk BJ, Leath CA 3rd.

Gynecol Oncol. 2017 Oct;147(1):98-103. doi: 10.1016/j.ygyno.2017.07.121. Epub 2017 Jul 23.

PMID:
28743369
8.

Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications.

Cory L, Latif N, Brensinger C, Zhang X, Giuntoli RL 2nd, Burger RA, Morgan M, Ko E.

Obstet Gynecol. 2017 Aug;130(2):285-295. doi: 10.1097/AOG.0000000000002141.

PMID:
28697106
9.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herráez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):711-717. doi: 10.1093/annonc/mdx011.

PMID:
28327917
10.

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.

Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA.

J Clin Oncol. 2016 Nov 10;34(32):3854-3863. doi: 10.1200/JCO.2016.68.1239.

11.

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA.

JAMA Oncol. 2016 Nov 1;2(11):1427-1433. doi: 10.1001/jamaoncol.2016.1842.

12.

Inherited Mutations in Women With Ovarian Carcinoma.

Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ.

JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.

13.

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA.

Ann Oncol. 2016 Jan;27(1):114-21. doi: 10.1093/annonc/mdv500. Epub 2015 Oct 20.

15.

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.

Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM.

J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3.

16.

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.

Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA.

Gynecol Oncol. 2015 Oct;139(1):17-22. doi: 10.1016/j.ygyno.2015.07.103. Epub 2015 Jul 26.

17.
18.

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

Cohn DE, Barnett JC, Wenzel L, Monk BJ, Burger RA, Straughn JM Jr, Myers ER, Havrilesky LJ.

Gynecol Oncol. 2015 Feb;136(2):293-9. doi: 10.1016/j.ygyno.2014.10.020. Epub 2014 Oct 23.

19.

American Society of Clinical Oncology position statement on obesity and cancer.

Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL, Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill JK, Wollins DS, Hudis CA.

J Clin Oncol. 2014 Nov 1;32(31):3568-74. doi: 10.1200/JCO.2014.58.4680. Epub 2014 Oct 1.

20.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX.

J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17.

21.

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.

Monk BJ, Pujade-Lauraine E, Burger RA.

Ann Oncol. 2013 Dec;24 Suppl 10:x53-x58. doi: 10.1093/annonc/mdt472. Review.

PMID:
24265406
22.

Ovarian cancer, version 2.2013.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209.

PMID:
24142821
23.

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.

J Clin Oncol. 2013 Dec 10;31(35):4400-6. doi: 10.1200/JCO.2013.49.7685. Epub 2013 Oct 14.

PMID:
24127448
24.

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, Bookman MA.

Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29.

25.

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Liang SX, Wenzel L.

Gynecol Oncol. 2013 Mar;128(3):573-8. doi: 10.1016/j.ygyno.2012.11.038. Epub 2012 Dec 4.

26.

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

PMID:
23138163
27.

Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.

Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA.

Gynecol Oncol. 2012 Dec;127(3):495-501. doi: 10.1016/j.ygyno.2012.09.002. Epub 2012 Sep 19.

28.
29.

Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group.

N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

30.

Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.

Burger RA.

Ann Oncol. 2011 Dec;22 Suppl 8:viii65-viii68. doi: 10.1093/annonc/mdr529.

PMID:
22180405
31.

Advances in ovarian cancer disease control.

Burger RA.

Gynecol Oncol. 2012 Jan;124(1):5-9. doi: 10.1016/j.ygyno.2011.11.011. No abstract available.

PMID:
22153126
32.

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI.

Gynecol Oncol. 2012 Mar;124(3):563-8. doi: 10.1016/j.ygyno.2011.11.035. Epub 2011 Dec 1.

33.

Epithelial ovarian cancer.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. No abstract available.

PMID:
21233246
34.

Overview of anti-angiogenic agents in development for ovarian cancer.

Burger RA.

Gynecol Oncol. 2011 Apr;121(1):230-8. doi: 10.1016/j.ygyno.2010.11.035. Epub 2011 Jan 8. Review.

PMID:
21215996
35.

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP.

Gynecol Oncol. 2010 Dec;119(3):484-90. doi: 10.1016/j.ygyno.2010.08.016. Epub 2010 Sep 25.

36.

Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.

Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA.

Gynecol Oncol. 2010 Dec;119(3):417-21. doi: 10.1016/j.ygyno.2010.08.010. Epub 2010 Sep 16.

37.

Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T.

Mol Cancer Ther. 2010 Aug;9(8):2411-22. doi: 10.1158/1535-7163.MCT-10-0169. Epub 2010 Jul 27.

38.

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Burger RA.

J Gynecol Oncol. 2010 Mar;21(1):3-11. doi: 10.3802/jgo.2010.21.1.3. Epub 2010 Mar 31.

39.

Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.

Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ.

Gynecol Oncol. 2010 Mar;116(3):452-8. doi: 10.1016/j.ygyno.2009.10.062. Epub 2009 Nov 13.

40.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM.

J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305.

41.

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD.

J Clin Oncol. 2009 Mar 1;27(7):1069-74. doi: 10.1200/JCO.2008.18.9043. Epub 2009 Jan 12.

42.

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.

Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP.

Gynecol Oncol. 2009 Mar;112(3):583-9. doi: 10.1016/j.ygyno.2008.11.013. Epub 2008 Dec 24.

43.

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M.

Clin Cancer Res. 2008 Dec 1;14(23):7781-9. doi: 10.1158/1078-0432.CCR-08-0243.

44.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.

Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.

45.

A new model of ovarian carcinogenesis may influence early detection strategies.

Burger RA.

Am J Obstet Gynecol. 2008 Apr;198(4):349-50. doi: 10.1016/j.ajog.2008.01.004. No abstract available.

PMID:
18395029
46.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W.

J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773.

PMID:
18024865
47.

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI.

J Clin Oncol. 2007 Nov 20;25(33):5165-71. Erratum in: J Clin Oncol. 2014 Nov 10;32(32):3686.

PMID:
18024863
48.

Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Spriggs DR, Brady MF, Vaccarello L, Clarke-Pearson DL, Burger RA, Mannel R, Boggess JF, Lee RB, Hanly M.

J Clin Oncol. 2007 Oct 1;25(28):4466-71.

PMID:
17906207
49.

Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma.

Arora N, Tewari D, Cowan C, Saffari B, Monk BJ, Burger RA.

Int J Gynecol Cancer. 2008 Mar-Apr;18(2):369-72. Epub 2007 Jul 11.

PMID:
17624986
50.

Experience with bevacizumab in the management of epithelial ovarian cancer.

Burger RA.

J Clin Oncol. 2007 Jul 10;25(20):2902-8. Review.

PMID:
17617521

Supplemental Content

Loading ...
Support Center